The efficiency of multi-target drugs: The network approach might help drug design

Trends in Pharmacological Sciences

Volumn 26, Issue 4, 2005, Pages 178-182

  Csermely, Péter ^a   Ágoston, Vilmos ^b   Pongor, Sándor ^b,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF BIOCHEMISTRY   (Hungary)

^c INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEOME; SALICYLIC ACID;

BINDING AFFINITY; COMPARATIVE STUDY; COMPUTER MODEL; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; GENOME; HIGH THROUGHPUT SCREENING; METABOLISM; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

EID: 15044349115     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.02.007     Document Type: Article

References (37)

1. Editorial Bigger is not always better Nature 418 2002 353
2. P. Szuromi Rethinking drug discovery Science 303 2004 1795
3. S. Huang Rational drug discovery: what can we learn from regulatory networks? Drug Discov. Today 7 2002 S163 S169
4. Kaelin, W.G. Jr (2004) Gleevec: prototype or outlier? Science STKE (225), pe12
5. A.A. Borisy Systematic discovery of multicomponent therapeutics Proc. Natl. Acad. Sci. U. S. A. 100 2003 7977 7982
6. Agoston, V. et al. Multiple hits confuse complex systems: a genetic network as an example. Phys. Rev. E. (in press) (http://www.arxiv.org/abs/q-bio. MN/0410026)
7. M.T. Ocampo Targeted deletion of mNth1 reveals a novel DNA repair enzyme activity Mol. Cell. Biol. 22 2002 6111 6121
8. B. Papp Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast Nature 429 2004 661 664
9. S.A. Lipton Turning down, but not off. Neuroprotection requires a paradigm shift in drug development Nature 428 2004 473
10. M.A. Rogawski Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - towards an understanding of their favorable tolerability Amino Acids 19 2000 133 149
11. P. Csermely Strong links are important, but weak links stabilize them Trends Biochem. Sci. 29 2004 331 334
12. D.J. Watts, and S.H. Strogatz Collective dynamics of 'small-world' networks Nature 393 1998 440 442
13. A.L. Barabasi, and R. Albert Emergence of scaling in random networks Science 286 1999 509 512
14. M.E.J. Newman The structure and function of complex networks SIAM Rev. 45 2003 167 256
15. J.M. Stuart A gene-coexpression network for global discovery of conserved genetic modules Science 302 2003 249 255
16. S. Bergmann Similarities and differences in genome-wide expression data of six organisms PLoS Biol. 2 2004 E9
17. A.I. Archakov Protein-protein interactions as a target for drugs in proteomics Proteomics 3 2003 380 391
18. T. Aoyama Neural networks applied to quantitative structure-activity relationship analysis J. Med. Chem. 33 1990 2583 2590
19. A. Vedani, and M. Dobler Multi-dimensional QSAR in drug research. Predicting binding affinities, toxicity and pharmacokinetic parameters Prog. Drug Res. 55 2000 105 135
20. Palsson, B. (2001) Methods for identifying drug targets based on genomic sequence data. US Patent 20020012939
21. M. Cascante Metabolic control analysis in drug discovery and disease Nat. Biotechnol. 20 2002 243 249
22. A. Cornish-Bowden, and M.L. Cardenas Metabolic analysis in drug design C. R. Biol. 326 2003 509 515
23. S.S. Shen-Orr Network motifs in the transcriptional regulation network of Escherichia coli Nat. Genet. 31 2002 64 68
24. R. Milo Network motifs: simple building blocks of complex networks Science 298 2002 824 827
25. T.S. Gardner Inferring genetic networks and identifying compound mode of action via expression profiling Science 301 2003 102 105
26. A.H.Y. Tong Global mapping of the yeast genetic interaction network Science 303 2004 808 813
27. P.Y. Lum Dicovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes Cell 116 2004 121 137
28. G. Giaever Chemogenomic profiling: identifying the functional interactions of small molecules in yeast Proc. Natl. Acad. Sci. U. S. A. 101 2004 793 798
29. J.R. Small, and H. Kacser Responses of metabolic systems to large changes in enzyme activities and effectors. 1. The linear treatment of unbranched chains Eur. J. Biochem. 213 1993 613 624
30. J.R. Small, and H. Kacser Responses of metabolic systems to large changes in enzyme activities and effectors. 2. The linear treatment of branched pathways and metabolite concentrations. Assessment of the general non-linear case Eur. J. Biochem. 213 1993 625 640
31. E. Szathmáry Do deleterious mutations act synergistically? Metabolic control theory provides a partial answer Genetics 133 1993 127 132
32. B.N. Kholodenko Untangling the wires: a strategy to trace functional interactions in signaling and gene networks Proc. Natl. Acad. Sci. U. S. A. 99 2002 12841 12846
33. J. Tegnér Reverse engineering gene networks: integrating genetic perturbations with dynamical modeling Proc. Natl. Acad. Sci. U. S. A. 100 2003 5944 5949
34. In Vivo Pharmacology Training Group The fall and rise of in vivo pharmacology Trends Pharmacol. 23 2002 13 18
35. C. von Clausewitz Vom Kriege (On War) 1832 Dümmlers Verlag Berlin
36. R. Albert Attack and error tolerance of complex networks Nature 406 2000 378 382
37. V. Latora, and M. Marchiori Efficient behaviour of small-world networks Phys. Rev. Lett. 87 2001 198701